Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study. uri icon

authors

  • Michael Nanna, MD, MHS
  • Knop, Filip K
  • Smolderen, Kim G
  • Mena-Hurtado, Carlos
  • Divino, Victoria
  • Zhao, Zhenxiang
  • Chen, Yan
  • Boland, Joanna
  • Song, Jinlin
  • Traina, Andrea
  • Ozer, Kerem

publication date

  • March 26, 2026